In a nutshell This study investigated the effectiveness and safety of short 15-minute panitumumab (Vectibix) injections. Researchers suggested that these injections were well tolerated with manageable side effects. Some background Panitumumab is a therapy that targets the EFGR receptor on cancer cells. This blocks cell growth which results in cell...
Read More
In a nutshell This study analyzed the survival outcomes of Hodgkin’s lymphoma (HL) patients who experience treatment failure after high-dose chemotherapy (HDC) and autologous hematopoietic stem cell transplantation (autoSCT). This study concluded that a second stem cell transplant with or without brentuximab vedotin (Adcetris) may lead to better...
Read More
In a nutshell This paper reviewed the effect of elozutumab (Empliciti) in the treatment of relapsed or refractory multiple myeloma. This study concluded that elozutumab with lenalidomide (Revlimid) and dexamethasone (Ozurdex) can be considered in relapsed or refractory multiple myeloma. Some background Multiple myeloma...
Read More
In a nutshell This study aimed to investigate the effectiveness and safety of ponatinib (Iclusig) for patients with chronic phase chronic myelogenous leukemia. This study concluded that ponatinib is safe and effective in this group of patients. Some background The Philadelphia chromosome (BCR-ABL1) is found in almost all patients with chronic...
Read More
In a nutshell This study aimed to investigate risk factors that influence the outcome of acute leukemia patients who experience relapse after hematopoietic stem cell transplant. This study concluded that certain factors, such as older age and not acheiving remission after relapse treatment, are associated with worse survival outcomes. Some...
Read More
In a nutshell This study investigated the safety and effectiveness of ibrutinib (Imbruvica), lenalidomide (Revlimid), and rituximab (Rituxan) given together to patients with relapsed or refractory (not responding to treatment) mantle cell lymphoma (MCL). The authors conclude that this combination is effective in these patients, but not better than the...
Read More
In a nutshell This paper compared the safety and effectiveness of daratumumab (Darzalex) in combination with bortezomib (Velcade) and dexamethasone (Ozurdex) in patients with relapsed or refractory multiple myeloma. Some background Multiple myeloma is a cancer of the plasma cells of the blood. Multiple myeloma can be refractory (not responding...
Read MoreIn a nutshell This study determined if progression-free survival (time from treatment before disease progression) could be improved in patients with relapsed or refractory Hodgkin’s lymphoma (HL) who received two cycles (tandem) of autologous hematopoietic stem cell transplantation (AHSCT). This study concluded that tandem AHSCT appears effective...
Read MoreIn a nutshell This study aimed to compare myeloablative transplant and a sequential approach treatment in patients with relapsed or refractory acute myeloid leukemia. This study concluded that both treatments had similar outcomes for these patients. Some background Allogeneic hematopoietic stem cell transplantation (HSCT) is the only...
Read MoreIn a nutshell This study aimed to examine the effectiveness and safety of enzalutamide (Xtandi) compared to bicalutamide (Casodex) in castration-resistant metastatic prostate cancer (cancer that does not respond to hormone therapy) patients in different age groups. This study concluded that enzalutamide improved outcomes for...
Read More
In a nutshell This study determined the real-world outcomes for patients with relapsed or refractory Hodgkin’s lymphoma (rrHL) who were given brentuximab vedotin (Adcetris) due to ineligibility for autologous stem cell transplant (ASCT). The study concluded that brentuximab vedotin is feasible and effective in patients with rrHL who are...
Read More
In a nutshell This phase 3 trial aims to determine the effectiveness of Iomab-B before an hematopoietic stem cell transplantation compared to conventional treatment. The outcome to be measured is remission (no disease) and survival. The details Acute myeloid leukemia is a type of bone marrow cancer. Iomab-B is a drug in development for...
Read More
